ARK Invest Sold 182,767 Shares of Strata Critical Medical; Analysts Continue to Favor the Stock

TLDR

• On April 13, 2026, ARK Invest divested 182,767 shares of Strata Critical Medical via two of its ETFs, a transaction valued at approximately $738,378.
• This activity forms part of a multi-day trend, as ARK also disposed of more than 75,000 shares on April 10.
• Strata Critical Medical operates as a healthcare logistics firm specializing in organ transplant transportation within the United States.
• Two Wall Street analysts have recently commenced coverage, assigning Buy ratings and setting price targets of $8.
• The consensus analyst price target of $9.08 suggests a potential upside exceeding 120% from the current share price of about $4.12.

(SeaPRwire) –   Cathie Wood’s ARK Invest has been methodically reducing its stake in Strata Critical Medical throughout the past week. The firm sold 182,767 shares on April 13, 2026, using two of its exchange-traded funds—the ARK Autonomous Technology & Robotics ETF and the ARK Space Exploration & Innovation ETF. The total value of these transactions was roughly $738,378.

Strata Critical Medical, Inc., SRTA

This was not an isolated event. ARK had previously sold over 75,000 shares on April 10, with additional sales recorded on other days during the same timeframe, indicating a conscious strategy to decrease its holdings in the company.

Strata Critical Medical is a small-capitalization company in the healthcare logistics sector. It operates one of the most extensive air transport and surgical service networks supporting organ transplant hospitals in the U.S. The company claims to be the sole provider of a comprehensive, end-to-end platform for organ transplant logistics.

The stock is presently priced near $4.12 per share. It finished trading on April 13 with a 2% gain and has advanced 51% over the last twelve months, categorizing it as a penny stock.

Analysts Still Bullish Despite ARK’s Selling

In contrast to ARK’s selling, two Wall Street analysts have recently initiated coverage on the stock with optimistic ratings.

Yuan Zhi, an analyst at B. Riley, started coverage with a Buy recommendation and an $8 price target. Zhi noted the company’s robust standing in the U.S. organ transplant market and its unique position as the only end-to-end logistics platform in this niche.

Bill Bonello, an analyst at Craig-Hallum, also initiated coverage with a Buy rating and an identical $8 price target. Bonello commented that the company has undergone significant transformations in the past year, but its growth potential is not yet priced into the stock.

Both analysts are of the opinion that investor assurance is likely to strengthen as the company’s financial performance becomes more transparent.

What the Numbers Show

According to TipRanks, Strata Critical Medical has a Strong Buy consensus rating, derived from three unanimous Buy recommendations.

The average price target among analysts is $9.08. This figure indicates a potential increase of more than 120% from the current price of around $4.12.

Bonello further remarked that existing analyst projections for the company might be cautious, implying that the actual growth opportunity could be greater than currently estimated.

ARK has not provided a public explanation for the continued sales, and no new purchases were reported on April 13.

The stock concluded trading at $4.12 on April 13, 2026, with three analysts maintaining Buy ratings and a consensus price target of $9.08.